Allogene Therapeutics Inc. (ALLO)
NASDAQ · Healthcare
Allogene Therapeutics Inc. Operating Income 2019–2025
Allogene Therapeutics Inc. annual/quarterly operating income history and growth rate from 2019 to 2025. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Allogene Therapeutics Inc. operating income for the quarter ending September 30, 2025 was -44.9 M, a 37.44% decrease year-over-year.
- Allogene Therapeutics Inc. operating income for the twelve months ending September 30, 2025 was -238.7 M, a 16.10% decrease year-over-year.
- Allogene Therapeutics Inc. annual operating income for 2025 was -209.3 M, a 23.38% decrease from 2024.
- Allogene Therapeutics Inc. annual operating income for 2024 was -273.2 M, a 16.64% decrease from 2023.
- Allogene Therapeutics Inc. annual operating income for 2023 was -327.7 M, a 2.32% decrease from 2022.
- Allogene Therapeutics Inc. annual operating income for 2022 was -335.5 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Allogene Therapeutics Inc. Operating Income — FAQ
Allogene Therapeutics Inc. (ALLO) operating income over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
What is Allogene Therapeutics Inc.'s operating income?
Allogene Therapeutics Inc. (ALLO) reported operating income of -$209M for fiscal 2025.
Where can I see ALLO's operating income history?
The chart and table above show Allogene Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.